Compare DexCom, Inc. (DXCM) vs Samsara Inc (IOT) Price & Performance

DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.

The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.

Samsara (IOT) trades at $41.71, up 2.96% with strong bullish momentum. The stock shows robust technical strength with bullish moving averages and trades near resistance at $42. Fundamentally, the company demonstrates impressive revenue growth, reaching $1.8B in 2026 with a positive net income turnaround to $91M. Recent Q2 2027 earnings beat expectations with $0.20 EPS versus $0.16 estimate, driven by 30% annual recurring revenue growth and expanding large-customer adoption.

Outlook remains positive with 75% analyst buy ratings and $51.15 consensus target, representing 23% upside. Key opportunities include enterprise standardization trends and AI integration through Samsara MCP. Risks include elevated valuation multiples (P/E 274.8, P/S 13.01) and potential cash flow pressure despite strong operational performance. The stock's recent 72% rally warrants monitoring for sustainability beyond multiple expansion.